A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Abroad (travel likely)RecruitingPHASE2

Conditions

Multiple Myeloma · AL Amyloidosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongshan Hospital Fudan University, Shanghai, China
Contact: Study coordinator (Jing Li) · li.jing6@zs-hospital.sh.cn · +86-18149780650

Study leads

Peng Liu
Principal Investigator
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Denver, United States

Registry for Adults With Plasma Cell Disorders (PCD's)

Multiple Myeloma · Amyloidosis · Cryoglobulinemia

Abroad (travel likely)Recruiting

Chapel Hill, United States

Plan Development for Giving Teclistamab in the Outpatient Setting

Multiple Myeloma · Relapsed Cancer · Refractory Cancer

Abroad (travel likely)RecruitingPHASE4

Toronto, Canada

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Houston, United States